1. Stephan AS*, Kosinska AD*, Mück-Häusl M, Muschaweckh A, Jäger C, Röder N, Heikenwälder M, Dembek C, Protzer U. (2023) Evaluation of the effect of CD70 co-expression on CD8 T cell response in protein-prime MVA-boost vaccination in mice. Vaccines 11(2):245. doi: 10.3390/vaccines11020245. *equal contribution.2. Su J, Brunner L, Ates-Öz EA, Sacherl J, Frank G, Kerth AK, Thiele F, Wiegand M, Mogler C, Aguilar JC, Knolle PA, Collin N, Kosinska AD*, Protzer U*. (2023) Activation of CD4 T cells determines the success of therapeutic hepatitis B vaccination in HBV-carrier mouse models. J Hepatol. 78(4):717-730. doi: 10.1016/j.jhep.2022.12.013. *equal contribution.3. Sacherl J*, Kosinska AD*, Kemter K, Kächele M, Laumen SC, Kerth HA, Ates-Öz E, Wolff LS, Su J, Essbauer S, Sutter G, Scholz M, Singethan K, Altrichter J, Protzer U. (2022) Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance. JHEP Rep. 13;5(2):100603. doi:10.1016/j.jhepr.2022.100603. *equal contribution.4. Kosinska AD, Festag J, Mück-Häusl M, Festag MM, Asen T, Protzer U. (2021) Immunogenicity and antiviral response of therapeutic hepatitis B vaccination in a mouse model of HBeAg-negative persistent HBV infection. Vaccines. 9(8):841. doi: 10.3390/vaccines9080841. 5. Michler T*, Kosinska AD*, Festag J, Bunse T, Su J, Ringelhan M, Imhof H, Grimm D, Steiger K, Mogler C, Heikenwalder M, Michel ML, Guzman CA, Milstein S, Sepp-Lorenzino L, Knolle P, Protzer U. (2020) Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice. Gastroenterology. 158(6):1762-1775. doi: 10.1053/j.gastro.2020.01.032. *equal contribution.6. Kosinska AD, Moeed A, Kallin N, Festag J, Su J, Steiger K, Michel ML, Protzer U*, Knolle PA*. (2019) Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection. Sci Rep. 25;9(1):10808. doi: 10.1038/s41598-019-47149-w. *equal contribution.7. Kosinska AD, Bauer T, Protzer U. (2017) Therapeutic vaccination for chronic hepatitis B. Curr Opin Virol. 23:75-81. doi: 10.1016/j.coviro.2017.03.011. 8. Kosinska AD, Pishraft-Sabet L, Wu W, Fang Z, Lenart M, Chen J, Dietze KK, Wang C, Kemper T, Lin Y, Yeh SH, Liu J, Dittmer U, Yuan Z, Roggendorf M, Lu M. (2017) Low hepatitis B virus-specific T-cell response in males correlates with high regulatory T-cell numbers in murine models. Hepatology. 66(1):69-83. doi: 10.1002/hep.29155.9. Kosinska AD, Zhang E, Johrden L, Liu J, Seiz PL, Zhang X, Ma Z, Kemper T, Fiedler M, Glebe D, Wildner O, Dittmer U, Lu M, Roggendorf M. (2013) Combination of DNA prime-adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog. 9(6):e1003391. doi: 10.1371/journal.ppat.1003391.10. Kosinska AD, Johrden L, Zhang E, Fiedler M, Mayer A, Wildner O, Lu M, Roggendorf M. (2012) DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model. J Virol. 86(17):9297-310. doi: 10.1128/JVI.00506-12.